NeoGenomics (NEO) vs UL Solutions (ULS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
NeoGenomics (NEO) has outperformed UL Solutions (ULS) over the past year, gaining 76.9% versus a loss of 8.6%. UL Solutions is the larger company by market cap ($13.55 billion vs $2.05 billion), about 6.6 times the size. On valuation, UL Solutions trades at a lower forward P/E (25.8x vs 47.1x for NeoGenomics).
UL Solutions pays a dividend yielding 0.82%, while NeoGenomics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEO | ULS |
|---|---|---|
| Share price | $15.97 | $67.13 |
| Market cap | $2.05B | $13.55B |
| 1-day change | -3.24% | -1.81% |
| YTD return | +35.80% | -14.87% |
| 1-year return | +76.85% | -8.62% |
| 5-year return | -63.19% | — |
| P/E ratio (TTM) | — | 27.07 |
| Forward P/E | 47.10 | 25.81 |
| EPS (TTM) | $-0.39 | $2.48 |
| Dividend yield | 0.00% | 0.82% |
| Annual dividend | $0.00 | $0.55 |
| Revenue (latest FY) | — | $3.05B |
| Revenue growth (YoY) | — | +6.38% |
| Net income (latest FY) | — | $325.00M |
| Gross margin | — | 49.46% |
| Operating margin | — | 17.10% |
| Net margin | — | 10.65% |
| 52-week high | $20.15 | $107.54 |
| 52-week low | $7.07 | $63.17 |
| Distance from 52-week high | -20.74% | -37.58% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +34.94% | +43.72% |
| Average volume | 2.36M | 893.81K |
| Shares outstanding | 128.48M | 78.14M |
| Employees | 2,500 | 14,587 |
| Sector | Health Care | Health Care |
| Industry | Precision Instruments | Precision Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UL Solutions is about 6.6 times larger than NeoGenomics by market value ($13.55B vs $2.05B).
- NEO has outperformed ULS by 85.5 percentage points over the past year.
About NeoGenomics
NEO stock →NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Health Care · Precision Instruments · 2,500 employees
About UL Solutions
ULS stock →UL Solutions Inc., together with its subsidiaries, provides testing, inspection and certification services and related software and advisory services worldwide. It operates through three segments: Industrial, Consumer, and Software and Advisory.
Health Care · Precision Instruments · 14,587 employees
NEO vs ULS FAQ
Which is bigger, NeoGenomics or UL Solutions?
UL Solutions (ULS) is larger, with a market capitalization of $13.55B compared with $2.05B for NeoGenomics (NEO).
Which stock has performed better over the past year, NEO or ULS?
NEO returned +76.85% over the past 12 months, compared with -8.62% for ULS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, NeoGenomics or UL Solutions?
UL Solutions pays a dividend yielding 0.82%, while NeoGenomics does not currently pay a regular dividend.
Are NeoGenomics and UL Solutions in the same industry?
Yes. Both are classified in the Precision Instruments industry within the Health Care sector.